BioSpace News Archive

Drug Development

Phase I Study Results Show First-in-class NBTXR3 Could Present as a Valuable Option for Patients With Hepatocellular Carcinoma or Liver Metastasis

NANOBIOTIX (Euronext : NANO – ISIN : FR0011341205 – the ‘‘Company’’), today announced encouraging findings from the Company’s phase I study evaluating first-in-class radioenhancer NBTXR3 activated by stereotactic body radiation (SBRT).

September 18, 2019
·
7 min read
Genetown

VBI Vaccines Announces Proposed Public Offering of Common Shares

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI or the Company), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that it has commenced an underwritten public offering of its common shares.

September 18, 2019
·
6 min read
Deals

Provention Bio Announces Proposed Public Offering of Common Stock - Sept. 18, 2019

Provention Bio, Inc. announced that it has commenced an underwritten public offering of shares of its common stock.

September 18, 2019
·
4 min read
Business

Stimwave Launches Post-Market Peripheral Neuropathy Pain Relief Randomized Controlled Trial for Pain Awareness Month

Stimwave Technologies, the leading innovator of wireless medical device bioelectronic technology, in honor of September Pain Awareness Month, today announces the launch of a new randomized clinical trial treating painful peripheral neuropathy, the “SMOOTH” study.

September 18, 2019
·
2 min read